Correlation Between Nucleus Software and Beta Drugs

Can any of the company-specific risk be diversified away by investing in both Nucleus Software and Beta Drugs at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nucleus Software and Beta Drugs into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Nucleus Software Exports and Beta Drugs, you can compare the effects of market volatilities on Nucleus Software and Beta Drugs and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nucleus Software with a short position of Beta Drugs. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nucleus Software and Beta Drugs.

Diversification Opportunities for Nucleus Software and Beta Drugs

-0.56

Correlation Coefficient

Nucleus Software  Beta Drugs

Excellent diversification

The 3 months correlation between Nucleus and Beta is -0.56. Overlapping area represents the amount of risk that can be diversified away by holding Nucleus Software Exports and Beta Drugs in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Beta Drugs and Nucleus Software is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nucleus Software Exports are associated (or correlated) with Beta Drugs. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Beta Drugs has no effect on the direction of Nucleus Software i.e., Nucleus Software and Beta Drugs go up and down completely randomly.

Pair Corralation between Nucleus Software and Beta Drugs

Assuming the 90 days trading horizon Nucleus Software Exports is expected to generate 1.23 times more return on investment than Beta Drugs. However, Nucleus Software is 1.23 times more volatile than Beta Drugs. It trades about 0.08 of its potential returns per unit of risk. Beta Drugs is currently generating about 0.09 per unit of risk. If you would invest  37,981  in Nucleus Software Exports on October 5, 2024 and sell it today you would earn a total of  70,589  from holding Nucleus Software Exports or generate 185.85% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	99.79%
Values	Daily Returns

Nucleus Software Exports  vs.  Beta Drugs

Nucleus Software Exports

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Nucleus Software Exports has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's technical and fundamental indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Beta Drugs

Risk-Adjusted Performance

9 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Beta Drugs are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, Beta Drugs unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Nucleus Software and Beta Drugs

The main advantage of trading using opposite Nucleus Software and Beta Drugs positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nucleus Software position performs unexpectedly, Beta Drugs can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Beta Drugs will offset losses from the drop in Beta Drugs' long position.

The idea behind Nucleus Software Exports and Beta Drugs pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.